2024 Travel Award Winners

The Cancer Immunotherapy Winter School Travel Awards are intended for individuals who will attend the program in person. The award amount, up to $1,000, will be reimbursed for eligible expenses associated with travel to attend the 2024 Cancer Immunotherapy Winter School program in person and/or registration for the Cancer Immunotherapy Winter School program.

We are pleased to announce the 2024 Cancer Immunotherapy Winter School Travel Award winners below. Thank you to everyone who applied.

Two of the five travel awards will be reserved for those who self-identify as individuals from underrepresented racial and ethnic groups in the Biomedical Sciences according to the NIH definition.The information collected in response to the self-identifying process will only be viewed by SITC staff and Cancer Immunotherapy Winter School program organizers.

Program Statement on Diversity, Equity and Inclusion
The Society for Immunotherapy of Cancer (SITC) understands the value of diversity, equity and inclusion and is committed to closing gaps within all facets of the organization, as well as ones in the field of immuno-oncology and biomedical sciences. Since 2018, SITC has been proactively following the NIH Statement on Diversity for those in underrepresented Populations in the U.S. Biomedical Sciences across planning, solicitation and implementation of all programming, including SITC’s Cancer Immunotherapy Winter School. In 2021, SITC formed the Diversity, Equity and Inclusion Task Force to ensure participation from nationally underrepresented racial and ethnic groups, individuals with disabilities, individuals from disadvantaged backgrounds and women from biomedical sciences throughout all society programs and initiatives.

Jacob J. Adashek, DO


Jacob J. Adashek, DO, is a medical oncology fellow at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Hospital. Dr. Adashek is particularly interested in precision medicine, personalized therapies, and first-in-human clinical trials. As a medical oncology fellow, he is being trained by world-renowned medical oncologists at the Johns Hopkins Hospital and caring for patients with a multitude of cancers. Dr. Adashek has published over 90 peer-reviewed articles in many prestigious journals, including Nature Clinical Reviews Oncology, JAMA Oncology, and among others. He has also presented his work at national and international conferences, including an oral presentation at the European Society for Medical Oncology Congress. Prior to starting his training at Johns Hopkins Hospital, Dr. Adashek was an internal medicine resident at the University of South Florida and Moffitt Cancer Center in Tampa. Before that, he completed a rigorous 7-year combined degree program, including an accelerated undergraduate degree at Pitzer College of the Claremont Colleges and a medical degree at Western University of Health Sciences in Pomona, California. In addition, he spent a year training in clinical research with a medical oncologist in the genitourinary oncology section of the City of Hope. Dr. Adashek is also a member of the American Society of Clinical Oncology and the American Association for Cancer Research.

Aseel Alsouqi, MD


Dr. Alsouqi is a third-year hematology/oncology fellow at the University of Pittsburgh Medical Center. She earned her medical degree from the University of Jordan Faculty of Medicine and completed her internal medicine residency training at Vanderbilt University Medical Center. Dr. Alsouqi is interested in aggressive non-Hodgkin lymphoma, particularly lymphoma involving the central nervous system. She was selected to participate in the ASCO/AACR Methods of Clinical Cancer Research Workshop in Vail to develop a clinical trial protocol in relapsed lymphoma after CAR-T therapy. She received the American Society of Hematology Summit on Immunotherapies abstract award for her work on reporting outcomes of CAR-T therapy in patients with secondary CNS lymphoma. She was also selected to participate in the Academy of Next Wave of Investigators in NHL and CLL. Dr. Alsouqi is pursuing a career as a clinical and translational investigator in CLL and lymphoma. She will study the mechanisms of resistance to cellular therapies in lymphoma and CLL and develop clinical trials using novel immune based- therapies to overcome this resistance. 

Opadeyi Oluseyi Michael, MBBS


Dr. Opadeyi Oluseyi Michael is a Trainee Specialist in Haematology at the Lagos University Teaching Hospital, Lagos, Nigeria. He obtained his MBBS degree at the University of Ilorin and Proceeded with his postgraduate degree programme. He had his Junior residency examination in 2019 and was awarded a Membership of the West Africa College of Physician (Hematology) and National Postgraduate Medical College of Nigeria, in September 2023, He bagged a prize award at the National Postgraduate Medical College of Nigeria Part 2 examination as the best candidate at the FMCPath examination in Hematology. He has an interest in Haemoto- oncology, particularly in the management of Lymphoproliferative disease. He is motivated by the novel agents and Cancer immunotherapies employed in managing haematologic malignancies and is highly optimistic about having a very impactful and engaging session at the 2024 Cancer Immunotherapy Winter School (CIWS).

Aleksei Tikhonov, PhD


Dr. Aleksei Tikhonov is a translational researcher with expertise in cancer immunology and immunotherapy, precision oncology, clinical chemistry, and circulating biomarkers. He earned his M.Sc. degree from the Higher Chemical College of the Russian Academy of Sciences in 2015 and his PhD in molecular biology and oncology from the Engelhardt Institute of Molecular Biology (EIMB RAS) in 2021. His PhD thesis focused on identifying novel circulating tumor markers in colorectal cancer using 3D-hydrogel microarray technology, which he developed and optimized during his doctoral studies.
Dr. Tikhonov is currently a postdoctoral fellow at Gustave Roussy in France, where he studies the role of auto-antibodies and anti-tumor antibodies in cancer immunotherapy. He collaborates with other researchers, clinicians, and biostatisticians and participates in clinical trials and translational studies. He has published over 20 articles and two patents and presented his results at international conferences. He is an active member of the SITC, ESMO, and EFLM committees. He also mentors junior researchers and students.

Taylor Uccello, PhD


Dr. Taylor Uccello received her PhD in Immunology in 2022 from the University of Rochester School of Medicine and Dentistry (Rochester, New York). Taylor’s doctoral research focused on improving radiation therapy for treating aggressive rectal cancer and her findings led to 3 first-author publications. In addition to her primary projects, Taylor also co-authored 8 publications during her doctoral studies. Taylor joined the E.L. Steele Laboratories at Massachusetts General Hospital and Harvard Medical School as a postdoctoral research fellow in August of 2022 and her work has focused on improving immunotherapy for pediatric medulloblastoma. Taylor was awarded an NIH T32 Training Grant in Cancer Neuroscience to support this research.